About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Hype and Glory | Main | Did He Say What They Thought He Said? »

May 22, 2002

Now Is the Peptide of Our Discontent

Email This Entry

Posted by Derek

Mickey Kaus, in his link to yesterday's post, mentioned that the company I work for seems down on peptides as drugs, and asked his readers to keep that in mind when they read my opinion on endostatin. All I can say is, it isn't just me (or my company.) You won't find much of anyone trying to develop a small protein as a drug. They're just too tempting for a variety of enzymes to tear up; this is a problem that's been known for decades.

Larger proteins, oddly, can have a bit more potential, although not for oral dosing. Depending on how they're folded, they can have a decent half-life in circulation, if you can get them that far (or, failing that, the effects they set off can be reasonably long-lasting.) Insulin and interferon are two examples that come to mind, both of which have to be injected, but work well.

There's been a huge amount of work devoted to making proteins stable enough to be given orally. Usually, the sorts of changes you have to make are also big enough to wipe out the activity you wanted, too. But there are some techniques that can work - attaching a long polyethylene glycol chain is a good one, known to the cognoscenti as "PEGylation." Glaxo SmithKline just signed a deal with a small company that is doing just this sort of thing to insulin. Many schemes have been hatched for encapsulating the proteins in some sort of vehicle that'll sneak them past the gut enzymes, with decidedly mixed success.

And there are ways to get around the digestion problem completely. It turns out that large proteins cross the nasal mucosa into the bloodstream surprisingly well (no, in case you're wondering, cocaine isn't in this category - it's a small molecule.) Several companies are working on this, with an inhaled form of insulin in advanced clinical trials (it's had its problems.)

For small proteins, there are all sorts of ways to modify the peptide bonds to make them less attractive to enzymes (putting in the wrong-handed amino acid, unusual methyl groups, other bonds instead of the usual amino acid amide connection, and so on.) It's a hard living, because many of these changes also get rid of the original protein's activity, and they don't always increase the levels in circulation, either. If you're going to go the peptidomimetic route (many have,) then you need some commitment, because it could take a while.

Comments (0) + TrackBacks (0) | Category: Cancer



Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry